214 related articles for article (PubMed ID: 29421063)
1. Targeted delivery of SNX-2112 by polysaccharide-modified graphene oxide nanocomposites for treatment of lung cancer.
Liu X; Cheng X; Wang F; Feng L; Wang Y; Zheng Y; Guo R
Carbohydr Polym; 2018 Apr; 185():85-95. PubMed ID: 29421063
[TBL] [Abstract][Full Text] [Related]
2. Carboxymethyl chitosan-mediated synthesis of hyaluronic acid-targeted graphene oxide for cancer drug delivery.
Yang H; Bremner DH; Tao L; Li H; Hu J; Zhu L
Carbohydr Polym; 2016 Jan; 135():72-8. PubMed ID: 26453853
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid-decorated graphene oxide nanohybrids as nanocarriers for targeted and pH-responsive anticancer drug delivery.
Song E; Han W; Li C; Cheng D; Li L; Liu L; Zhu G; Song Y; Tan W
ACS Appl Mater Interfaces; 2014 Aug; 6(15):11882-90. PubMed ID: 25000539
[TBL] [Abstract][Full Text] [Related]
4. Receptor-targeted, drug-loaded, functionalized graphene oxides for chemotherapy and photothermal therapy.
Thapa RK; Choi JY; Poudel BK; Choi HG; Yong CS; Kim JO
Int J Nanomedicine; 2016; 11():2799-813. PubMed ID: 27358565
[TBL] [Abstract][Full Text] [Related]
5. Lactobionic acid and carboxymethyl chitosan functionalized graphene oxide nanocomposites as targeted anticancer drug delivery systems.
Pan Q; Lv Y; Williams GR; Tao L; Yang H; Li H; Zhu L
Carbohydr Polym; 2016 Oct; 151():812-820. PubMed ID: 27474628
[TBL] [Abstract][Full Text] [Related]
6. Hybrid graphene oxide/polysaccharide nanocomposites with controllable surface properties and biocompatibility.
Andreeva TD; Stoichev S; Taneva SG; Krastev R
Carbohydr Polym; 2018 Feb; 181():78-85. PubMed ID: 29254036
[TBL] [Abstract][Full Text] [Related]
7. Enzymatically cross-linked hyaluronic acid/graphene oxide nanocomposite hydrogel with pH-responsive release.
Song F; Hu W; Xiao L; Cao Z; Li X; Zhang C; Liao L; Liu L
J Biomater Sci Polym Ed; 2015; 26(6):339-52. PubMed ID: 25598448
[TBL] [Abstract][Full Text] [Related]
8. A Targeted Nano Drug Delivery System of AS1411 Functionalized Graphene Oxide Based Composites.
Liu B; Yang W; Che C; Liu J; Si M; Gong Z; Gao R; Yang G
ChemistryOpen; 2021 Apr; 10(4):408-413. PubMed ID: 33605540
[TBL] [Abstract][Full Text] [Related]
9. Folic acid-grafted bovine serum albumin decorated graphene oxide: An efficient drug carrier for targeted cancer therapy.
Ma N; Liu J; He W; Li Z; Luan Y; Song Y; Garg S
J Colloid Interface Sci; 2017 Mar; 490():598-607. PubMed ID: 27923144
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-functionalised single-walled carbon nanotube-mediated drug delivery of SNX-2112 in cancer cells.
Zheng L; Wu S; Tan L; Tan H; Yu B
J Biomater Appl; 2016 Sep; 31(3):379-86. PubMed ID: 27231263
[TBL] [Abstract][Full Text] [Related]
11. Targeted Delivery of Docetaxel by Use of Transferrin/Poly(allylamine hydrochloride)-functionalized Graphene Oxide Nanocarrier.
Nasrollahi F; Varshosaz J; Khodadadi AA; Lim S; Jahanian-Najafabadi A
ACS Appl Mater Interfaces; 2016 Jun; 8(21):13282-93. PubMed ID: 27158834
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid and Arg-Gly-Asp peptide modified Graphene oxide with dual receptor-targeting function for cancer therapy.
Guo Y; Xu H; Li Y; Wu F; Li Y; Bao Y; Yan X; Huang Z; Xu P
J Biomater Appl; 2017 Jul; 32(1):54-65. PubMed ID: 28554233
[TBL] [Abstract][Full Text] [Related]
13. Phospholipid-stabilized mesoporous carbon nanospheres as versatile carriers for systemic delivery of amphiphobic SNX-2112 (a Hsp90 inhibitor) with enhanced antitumor effect.
Zhang X; Zhang T; Ye Y; Chen H; Sun H; Zhou X; Ma Z; Wu B
Eur J Pharm Biopharm; 2015 Aug; 94():30-41. PubMed ID: 25936860
[TBL] [Abstract][Full Text] [Related]
14. Heparin-reduced graphene oxide nanocomposites for curcumin delivery: in vitro, in vivo and molecular dynamics simulation study.
Shi X; Wang Y; Sun H; Chen Y; Zhang X; Xu J; Zhai G
Biomater Sci; 2019 Feb; 7(3):1011-1027. PubMed ID: 30604794
[TBL] [Abstract][Full Text] [Related]
15. Quercetin-mediated synthesis of graphene oxide-silver nanoparticle nanocomposites: a suitable alternative nanotherapy for neuroblastoma.
Yuan YG; Wang YH; Xing HH; Gurunathan S
Int J Nanomedicine; 2017; 12():5819-5839. PubMed ID: 28860751
[TBL] [Abstract][Full Text] [Related]
16. Graphene oxide stabilized by PLA-PEG copolymers for the controlled delivery of paclitaxel.
Angelopoulou A; Voulgari E; Diamanti EK; Gournis D; Avgoustakis K
Eur J Pharm Biopharm; 2015 Jun; 93():18-26. PubMed ID: 25817600
[TBL] [Abstract][Full Text] [Related]
17. PEGylated graphene oxide/Fe3O4 nanocomposite: Synthesis, characterization, and evaluation of its performance as de novo drug delivery nanosystem.
Jafarizad A; Taghizadehgh-Alehjougi A; Eskandani M; Hatamzadeh M; Abbasian M; Mohammad-Rezaei R; Mohammadzadeh M; Toğar B; Jaymand M
Biomed Mater Eng; 2018; 29(2):177-190. PubMed ID: 29457592
[TBL] [Abstract][Full Text] [Related]
18. Graphene oxide as a nanocarrier for controlled release and targeted delivery of an anticancer active agent, chlorogenic acid.
Barahuie F; Saifullah B; Dorniani D; Fakurazi S; Karthivashan G; Hussein MZ; Elfghi FM
Mater Sci Eng C Mater Biol Appl; 2017 May; 74():177-185. PubMed ID: 28254283
[TBL] [Abstract][Full Text] [Related]
19. Graphene oxide-chitosan nanocomposites for intracellular delivery of immunostimulatory CpG oligodeoxynucleotides.
Zhang H; Yan T; Xu S; Feng S; Huang D; Fujita M; Gao XD
Mater Sci Eng C Mater Biol Appl; 2017 Apr; 73():144-151. PubMed ID: 28183591
[TBL] [Abstract][Full Text] [Related]
20. Characterisation and drug release performance of biodegradable chitosan-graphene oxide nanocomposites.
Justin R; Chen B
Carbohydr Polym; 2014 Mar; 103():70-80. PubMed ID: 24528702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
